Teva first in the US with a rival to Cialis

Teva will compete for a share of the near US$2 billion Cialis (tadalafil) market in the US, with the launch of its first-to-file generic version of the treatment for erectile dysfunction and signs and symptoms of benign prostatic hyperplasia.